Gilead Sciences (GILD) to Release Earnings on Tuesday

Gilead Sciences (NASDAQ:GILD) will likely be issuing its Q4 2025 results after the market closes on Tuesday, February 10th. Analysts expect the company to announce earnings of $1.87 per share and revenue of $7.68 billion for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 10, 2026 at 4:30 PM ET.

Gilead Sciences Stock Up 2.1%

Shares of NASDAQ:GILD opened at $152.50 on Friday. The company has a quick ratio of 1.31, a current ratio of 1.45 and a debt-to-equity ratio of 1.03. The company has a market capitalization of $189.20 billion, a P/E ratio of 23.64, a P/E/G ratio of 0.80 and a beta of 0.36. Gilead Sciences has a 52-week low of $93.37 and a 52-week high of $153.13. The stock’s fifty day simple moving average is $127.38 and its 200-day simple moving average is $120.99.

Insider Activity at Gilead Sciences

In other news, Director Kelly A. Kramer sold 2,805 shares of the company’s stock in a transaction on Friday, November 28th. The stock was sold at an average price of $127.10, for a total transaction of $356,515.50. Following the completion of the sale, the director directly owned 1,339 shares in the company, valued at $170,186.90. This represents a 67.69% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CEO Daniel Patrick O’day sold 115,640 shares of the stock in a transaction on Thursday, February 5th. The stock was sold at an average price of $150.00, for a total value of $17,346,000.00. Following the completion of the transaction, the chief executive officer directly owned 613,912 shares in the company, valued at $92,086,800. This trade represents a 15.85% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 373,037 shares of company stock worth $50,731,512. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Gilead Sciences

Several hedge funds and other institutional investors have recently modified their holdings of the company. Palisade Asset Management LLC acquired a new stake in Gilead Sciences during the 3rd quarter worth approximately $46,000. Wealth Watch Advisors INC purchased a new stake in Gilead Sciences during the third quarter worth approximately $60,000. Quantbot Technologies LP acquired a new stake in shares of Gilead Sciences in the third quarter worth $72,000. Binnacle Investments Inc increased its position in shares of Gilead Sciences by 14.3% in the second quarter. Binnacle Investments Inc now owns 702 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 88 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd raised its stake in shares of Gilead Sciences by 135.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 713 shares of the biopharmaceutical company’s stock valued at $79,000 after acquiring an additional 410 shares during the period. 83.67% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have issued reports on the stock. JPMorgan Chase & Co. upped their target price on shares of Gilead Sciences from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Friday, October 31st. Daiwa Securities Group upped their price objective on shares of Gilead Sciences from $128.00 to $129.00 and gave the company an “outperform” rating in a research note on Thursday, November 13th. Mizuho raised their target price on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a research report on Friday, November 21st. TD Cowen boosted their price target on Gilead Sciences from $125.00 to $145.00 and gave the company a “buy” rating in a report on Thursday, January 29th. Finally, Wolfe Research increased their price target on Gilead Sciences from $150.00 to $155.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $136.73.

About Gilead Sciences

Gilead Sciences, Inc, founded in 1987 and headquartered in Foster City, California, is a biopharmaceutical company focused on the discovery, development and commercialization of medicines in areas of high unmet medical need. The company initially built its reputation in antiviral therapies and has since expanded into oncology, cell therapy and inflammatory diseases. Gilead operates a global research and commercial organization, conducting clinical development and selling medicines in markets around the world.

Gilead’s product portfolio is anchored by antiviral therapies for HIV and viral hepatitis.